MDGL
BULL
2026-05-15
Overnight Institutional Flow Signal
Score
5/10
Move
4.0%
Flow
$2.8M
AI Trade Thesis
MDGL BULL. Truist's survey-driven PT hike to $709 and the 127% YoY revenue growth in Q1 provide a high-conviction fundamental floor. As a leader in the 'Other' sector cluster (39 candidates), the trade targets the $600 psychological resistance with entry at current levels. Risk: Potential for higher-than-expected SG&A in Q2 as marketing for Rezdiffra scales.
Flow Breakdown
Call Volume
$1.6M
Put Volume
$1.1M
Flow Intent
DIRECTIONAL
Catalyst
Analyst Upgrade
Recommended Setup
ContractO:MDGL260618C00630000
Contract Score5.697/10
Risk/Reward0.4:1
Delta0.15
Key Levels
Resistance$559.00
Support$490.13
Price$539.89
SMA 50 / 200$497 / $478
52W Range$265 — $615
News & Catalyst Analysis
Key Headline
Truist raises Madrigal Pharmaceuticals price target to $709 on strong Rezdiffra survey results
News Summary
MDGL is benefiting from a high-conviction price target increase to $709 by Truist Securities, which cited proprietary survey data showing Rezdiffra is the top choice for physicians treating MASH. This fundamental tailwind is amplified by a recent Q1 earnings beat featuring 127% year-over-year revenue growth, indicating the commercial launch is exceeding initial market expectations.
Flow Intent Analysis
The $1.6M bullish flow follows a significant fundamental reassessment of peak sales potential by Truist, suggesting institutional positioning for a longer-term valuation re-rating rather than short-term hedging.
One email a week. Catch up in five minutes.
The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.